AstraZeneca PLC (AZNN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AstraZeneca PLC (AZNN) has a cash flow conversion efficiency ratio of 0.048x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (MX$2.34 Billion ≈ $134.78 Million USD) by net assets (MX$48.72 Billion ≈ $2.80 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AZNN defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
AstraZeneca PLC - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how AstraZeneca PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AstraZeneca PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AstraZeneca PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LVMH Moët Hennessy - Louis Vuitton Société Européenne
PA:MC
|
0.118x |
|
Morgan Stanley
SA:MSBR34
|
-0.030x |
|
Palantir Technologies Inc.
NASDAQ:PLTR
|
0.105x |
|
Agricultural Bank of China Ltd Class A
SHG:601288
|
0.359x |
|
General Electric Company
SA:GEOO34
|
0.100x |
|
Royal Bank of Canada
TO:RY
|
-0.106x |
|
Industrial and Commercial Bank of China Ltd
SHG:601398
|
0.325x |
|
AstraZeneca PLC
NASDAQ:AZN
|
0.071x |
Annual Cash Flow Conversion Efficiency for AstraZeneca PLC (2014–2025)
The table below shows the annual cash flow conversion efficiency of AstraZeneca PLC from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see AstraZeneca PLC stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | MX$48.72 Billion ≈ $2.80 Billion |
MX$14.57 Billion ≈ $838.80 Million |
0.299x | +3.09% |
| 2024-12-31 | MX$40.87 Billion ≈ $2.35 Billion |
MX$11.86 Billion ≈ $682.60 Million |
0.290x | +9.68% |
| 2023-12-31 | MX$39.17 Billion ≈ $2.25 Billion |
MX$10.36 Billion ≈ $596.39 Million |
0.265x | -0.03% |
| 2022-12-31 | MX$37.06 Billion ≈ $2.13 Billion |
MX$9.81 Billion ≈ $564.45 Million |
0.265x | +74.37% |
| 2021-12-31 | MX$39.29 Billion ≈ $2.26 Billion |
MX$5.96 Billion ≈ $343.17 Million |
0.152x | -50.54% |
| 2020-12-31 | MX$15.64 Billion ≈ $899.97 Million |
MX$4.80 Billion ≈ $276.18 Million |
0.307x | +50.87% |
| 2019-12-31 | MX$14.60 Billion ≈ $840.00 Million |
MX$2.97 Billion ≈ $170.87 Million |
0.203x | +9.12% |
| 2018-12-31 | MX$14.04 Billion ≈ $808.24 Million |
MX$2.62 Billion ≈ $150.67 Million |
0.186x | -13.30% |
| 2017-12-31 | MX$16.64 Billion ≈ $957.75 Million |
MX$3.58 Billion ≈ $205.91 Million |
0.215x | -13.54% |
| 2016-12-31 | MX$16.67 Billion ≈ $959.31 Million |
MX$4.14 Billion ≈ $238.55 Million |
0.249x | +38.46% |
| 2015-12-31 | MX$18.51 Billion ≈ $1.07 Billion |
MX$3.32 Billion ≈ $191.30 Million |
0.180x | -50.01% |
| 2014-12-31 | MX$19.65 Billion ≈ $1.13 Billion |
MX$7.06 Billion ≈ $406.19 Million |
0.359x | -- |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo,… Read more